Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
![]() |
- The Phase 3 BiPASS™ study of Illuccix® and Gozellix® for prostate cancer imaging in the pre-biopsy setting has completed enrollment of 350 patients.
- Telix has positively engaged with the FDA on a New Drug Application (NDA) pathway in the U.S. that would support new product reimbursement and broaden access to 68Ga-PSMA-PET imaging...
Read more: Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway





